DNA in tumor cells

The phrase "DNA in tumor cells at sites of increased bone turnover" refers to the presence of **tumor-derived genetic material**—either as part of intact disseminated or circulating tumor cells, or as free nucleic acids—in areas where bone remodeling is active. This is not a specific molecular target such as a receptor, enzyme, or transporter. Instead, it describes a **biomarker context** used for prognosis and disease monitoring in cancers with high risk of bone metastasis, such as breast and prostate cancer[1][3]. Detection of disseminated tumor cell (DTC) DNA in the bone marrow has been shown to predict recurrence and poor prognosis[1]. However, "DNA" itself is not considered a druggable therapeutic target; rather, it serves as an indicator for metastatic activity and patient stratification. This entry is considered incorrect as a canonical drug target because it does not refer to a single protein or defined molecular entity but rather to genetic material from cancer cells present at specific anatomical sites.

Other names

Tumor cell DNACirculating tumor DNA (ctDNA)Disseminated tumor cell DNA (DTC-DNA)